QuidelOrtho (QDEL)
(Delayed Data from NSDQ)
$69.22 USD
+0.49 (0.71%)
Updated Dec 1, 2023 04:00 PM ET
After-Market: $69.20 -0.02 (-0.03%) 7:58 PM ET
3-Hold of 5 3
A Value F Growth B Momentum C VGM
Price, Consensus and EPS Surprise
QDEL 69.22 +0.49(0.71%)
Will QDEL be a Portfolio Killer in December?
Zacks Investment Research is releasing its prediction for QDEL based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for QDEL
QuidelOrtho (QDEL) Q3 Earnings Top Estimates, Margins Down
QuidelOrtho (QDEL) Q3 Earnings: Taking a Look at Key Metrics Versus Estimates
QDEL: What are Zacks experts saying now?
Zacks Private Portfolio Services
Medical Device Stocks to Watch for Earnings on Nov 1: MCK & More
Haemonetics (HAE) Reports Next Week: Wall Street Expects Earnings Growth
Analysts Estimate QuidelOrtho (QDEL) to Report a Decline in Earnings: What to Look Out for
Other News for QDEL
U.S. to distribute more free COVID tests
QuidelOrtho to Participate in the Evercore ISI Conference
Diagnostics Firm QuidelOrtho Contemplates Selling Transfusion Medicine Arm Valued Up To $2B: Report
QuidelOrtho evaluating sale of transfusion medicine business - report
ArrowMark Colorado Holdings LLC Reduces Stake in Sonendo Inc